Drug General Information
Drug ID
D05VCA
Former ID
DIB009997
Drug Name
IP10.C8-1
Synonyms
DPIV/AAP inhibitor (PETIR, tranplant rejection), IMTM; IP10.C8-1 (PETIR, tranplant rejection), IMTM
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 2 [1]
Company
Immunotech
Target and Pathway
Target(s) Aminopeptidase N Target Info Inhibitor [2], [1]
Dipeptidyl peptidase IV Target Info Inhibitor [2], [1]
BioCyc Pathway Glutathione-mediated detoxification
KEGG Pathway Glutathione metabolism
Metabolic pathways
Renin-angiotensin system
Hematopoietic cell lineagehsa04974:Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database C-MYB transcription factor network
PathWhiz Pathway Glutathione Metabolism
Reactome Metabolism of Angiotensinogen to Angiotensins
WikiPathways Metabolism of Angiotensinogen to Angiotensins
Cardiac Progenitor Differentiation
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in leukocytes - TarBase
Glutathione metabolism
References
REF 1Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
REF 2ClinicalTrials.gov (NCT00824980) Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.